Dr. Velculescu led the first genome-wide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human cancer. His team’s discoveries have led to new FDA approved therapies against PI3K (alpelisib) and IDH1 (ivosidenib), and diagnostic tests for comprehensive tumor profiling. More recently, his group has invented non-invasive liquid biopsy approaches for early detection and monitoring of cancer patients. His work has created the foundation of precision oncology and has benefited thousands of patients worldwide.